Should I Buy GUTS? GUTS 2026 Analysis

Should You Buy Fractyl Health Inc (GUTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.860

1 Day change

0.94%

52 Week Range

3.030

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Fractyl Health Inc (GUTS) does not present a strong buy opportunity for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, has no recent news or financial data to support growth trends, and technical indicators suggest a neutral trend. Additionally, there are no proprietary trading signals or notable trading activity from insiders, hedge funds, or Congress to indicate strong confidence in the stock.

Technical Analysis

The MACD is positive and expanding, indicating mild bullish momentum. RSI is neutral at 63.247, and moving averages are converging, suggesting no clear trend. Key resistance levels are at 0.867 and 0.926, while support levels are at 0.676 and 0.617.

Positive Catalysts

NULL identified. No recent news, no significant insider or hedge fund activity, and no recent Congress trading data.

Neutral/Negative Catalysts

Lack of financial data, no significant trading trends, and neutral technical indicators.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

4 Analyst Rating

Wall Street analysts forecast GUTS stock price to rise

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.850

Low

Averages

High

Current: 0.850

Low

Averages

High

H.C. Wainwright

Buy

maintain

AI Analysis

2026-03-17

Reason

H.C. Wainwright

Price Target

AI Analysis

2026-03-17

maintain

Buy

Reason

AH.C. Wainwright says Fractyl Health's January announcement of the six-month randomized data from the REMAIN-1 midpoint cohort evaluating Revita duodenal mucosal resurfacing maintenance after GLP-1 drug discontinuation triggered a 65% selloff in the shares. Investors focused on "critical friction points, including lack of statistical significance and weight-regain kinetics," the analyst tells investors in a research note. H.C. Wainwright, however, interpreted the results as consistent with the overall Revita trajectory observed in the pilot REVEAL-1 open-label extension cohort and earlier REMAIN-1 midpoint readouts. The firm has positive expectations for the REMAIN-1 pivotal readout anticipated in Q4. The readout could position Revita as a one-time procedural backbone for patients who discontinue GLP-1 therapy, Wainwright contends. It tells investors to "take a breath," saying Revita's data warrant a closer look. The firm has a Buy rating on Fractyl with an $8 price target.

BofA

Buy

downgrade

$5 -> $2

2026-01-30

Reason

BofA

Price Target

$5 -> $2

2026-01-30

downgrade

Buy

Reason

BofA lowered the firm's price target on Fractyl Health to $2 from $5 and keeps a Buy rating on the shares after the company provided new, six-month randomized controlled data of its Revita procedure in weight maintenance post-discontinuation of a GLP1 therapy. The "data were not perfect," but the firm thinks the pivotal results should benefit from a much larger sample size and optimization of trial execution, says the analyst, who lowered the firm's sales forecast pending clarity on the profile strength based on additional data.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GUTS

Unlock Now

GUTS Should I Buy

GUTS Should I Buy

Should You Buy Fractyl Health Inc (GUTS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch